Our co-founders Dr. Joe Loscalzo and Dr. Albert-Laszlo Barabasi pioneered the building of the map of human biology – the Human Interactome – that explains how proteins expressed from genes interact to cause specific disease phenotypes, providing the wiring diagram needed to interpret dynamic molecular data from patients to determine an individual’s unique disease biology.Science publications
A global business leader and entrepreneur at heart, Alif draws from his scientific background in systems biology, network theory, and engineering at Scipher. Alif has successfully led cross-disciplinary teams in technology and business across Asia, Europe and the Americas – raising over $225 million in venture and private equity capital. Previously with BCI (acquired 2000), Alfa Laval (IPO 2002), and Myriant (acquired 2014), Alif received his MSc degree in Chemical and Genetic Engineering from Lund Institute of Technology, Sweden.
Slava has been named one of the Top 100 AI Leaders in Drug Discovery and Advanced Healthcare and is a frequent speaker at some of the most prolific industry events. Slava is the inventor of several issued and pending patent applications and has published more than 20 peer-reviewed articles in computational biology, artificial intelligence, and molecular biology. Slava’s experience includes developing data-driven technologies for target discovery and precision medicine and launching multiple commercial diagnostic products at Berg and GNS Healthcare. Slava started his career working for Genzyme Genetics where he developed novel statistical approaches for high-throughput “omics” data. Dr. Akmaev holds a Ph.D. in Applied Mathematics from the University of Colorado at Boulder.
Jerry specializes in the successful reimbursement of novel molecular diagnostic platforms, having obtained broad payer coverage with value-based payment from Medicare, employers and commercial payers. He has built an illustrious career of working with key payers to ensure product coverage upon market launch at companies such as Foundation Medicine, Genzyme Genetics and Corning Metpath. Most recently, Jerry was the Executive Vice President at CDx Diagnostics.
Since joining Scipher Medicine in May 2020, Brian has brought his 20+ years of successful commercialization leadership experience to bear. Top achievements prior to joining include the successful introduction of numerous novel LDTs and culminating 5 years of executive management at Exagen Inc with a successful IPO. Prior to his work at Exagen, Brian delivered significant growth to organizations including Inova Diagnostics, Hologic, Cypress Bioscience, and Quidel. An industry veteran, Brian has received numerous awards including being recognized as the Diagnostics Marketer of The Year by the Medical Marketing Association. In every instance, his professional efforts are dedicated toward improving healthcare through better care, improved patient outcomes, and reduced overall costs. Brian earned a Master of Business Administration from University of California, Irvine, and a Bachelor of Arts in Business from the University of San Diego.
Jeff brings 25 years of legal expertise within the healthcare and technology industries to lead Scipher’s legal, compliance and finance function. Previously, he oversaw global commercial and intellectual property functions for Quintiles, the world’s largest contract research organization (CRO), and he served as VP & General Counsel of Outcome Sciences, Inc., a CRO acquired by Quintiles. Earlier in his career, Jeff practiced law at Goodwin Procter LLP in Boston, MA. Jeff’s background spans a wide spectrum of businesses from startups to Fortune 500 companies, and includes venture capital financing, managing SEC and corporate matters for publicly traded companies, commercial contracting, and mergers & acquisitions. Jeff earned his J.D. from the University of Virginia School of Law and a B.A. in Political Science from Brown University.
Alison joined Scipher Medicine with 20+ years of Human Resources experience. Prior to joining Scipher, she was the Practice Leader at the Dominis Group where she worked with executives of various stage startup companies to scale their organizations. Her passion is in developing individuals while growing and leading high-performance teams. Alison has also worked in HR and Talent Acquisition for Akamai Technologies, Allergan and Fidelity Investments. Alison holds a BA in Political Science from University of Massachusetts, Amherst.
Dr. Benjamin served as the 18th U.S. Surgeon General from 2009 to 2013. She was also chair of the National Prevention Council, composed of 17 cabinet-level heads of federal agencies that released the first-ever National Prevention Strategy, whose goal was to change our healthcare system from one based on sickness and disease, to one of wellness and prevention. Dr. Benjamin serves on the boards of Kaiser Foundation Hospitals and Health Plan, Ascension Health, and 3 publicly traded healthcare companies. As a family physician, and Founder of BayouClinic, Inc, Dr. Benjamin is one of the nation’s leading voices on population and preventive health issues.
Byerwalter is Chairman Emeritus of the SRI International. She serves on the Stanford Health Care Board of Directors, where she was Chairman of the Board of Directors from 2006 through 2013, and served as the Interim President and CEO of Stanford Health Care in 2016. Byerwalter also sits on the Board of Directors of Pacific Life, Franklin Resources, and Lucile Packard Children’s Hospital. She holds a B.A. degree from Stanford University and an MBA from Harvard Business School.
Human Genome Project completed.
Our founders Drs. Joseph Loscalzo and Laszlo Barabasi begin building the map of human disease biology that explains how proteins expressed from the human genome interact to cause specific diseases.
The map grows to cover 89% of all proteins in human cells, revealing the underlying biological processed causing many of the most common and difficult to treat diseases.
Scipher Medicine is founded.
Research begins to develop predictive drug response tests.
Scipher applies its research to develop a blood test for predicting drug response to anti-TNF therapies, after months of researching and surveying the healthcare system to identify significant clinical and financial pain points.
September: Scipher completes its Series A funding led by Khosla Ventures.
December: Scipher completes the observational study for its anti-TNF response test in rheumatoid arthritis.
United HealthGroup invests into Scipher.
PrismRA study reads out positive and Scipher launches the test commercially.
Signs pharma deal with Galapagos to develop targets that are specific to biologically similar sub populations of patients.